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Objective/Background: The characterization of tuberculosis (TB) patients as slow or fast
responders post anti-TB treatment has always been a matter of tremendous interest as
slow responders are most likely to relapse and/or develop complications. Pulmonary tissue
healing as assessed with radiology is the only available tool for tissue recovery but is not
predictive at intake. The objective of the current study was to assess biomarkers associated
with fast and slow recovery in TB patients at recruitment.
Methods: Pulmonary TB patients (N = 15) were assessed for radiological recovery serially in
parallel with clinical signs and symptoms, hematological parameters, and plasma cytoki-
nes at 0 months, 6 months, 12 months, and 24 months. On the basis of differential radio-
logical healing, patients were characterized into slow (>12 months), intermediate
(<12 months), and fast (<6 months) responders.
Results: Baseline plasma cytokines (interleukin [IL]-2, -4, -6, -10, tumor necrosis factor-a,
and interferon-c) were determined using cytometric bead array. IL-2 and -4 were able to
accurately differentiate slow and fast responders into two distinct clusters using hierarchal
clustering analysis. Compared with fast responders, slow responders showed significantly
high IL-2 and -4 at baseline (p = .001 Mann–Whitney U test).
Conclusion: In-depth analysis of cytokines and its association with radiological recovery in
TB patients may be useful in monitoring TB patients postchemotherapy for both clinicians
and TB control program.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Pulmonary tuberculosis (TB) is the transmissible form of TB
which spreads through the inhalation of droplet nuclei.
Mycobacterium tuberculosis is first taken up by alveolar macro-phages, which after engulfment activate other immune cells
(neutrophils and dendritic cells) for clearance and presenta-
tion of mycobacterial antigens to different subsets of T cells
to secrete cell activating and differentiating cytokines which
orchestrate an adaptive immune response. Containment or0, Karachi
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immune activation in the form of a granuloma formation
and walling off the infection. Generally granulomas are made
up of a central core of infected cells surrounded by macro-
phages and multinucleated giant cells with an outer layer of
lymphocytes. Granulomas are further divided into the follow-
ing three categories: classical caseous, central necrotizing,
and fibrotic granuloma [1]. The role of granulomas in TB is
not yet clearly defined in terms of its role in protection or pro-
gression of infection and disease onset [2]. Radiological find-
ings define the extent of tissue involvement [2] into
minimal disease (PMN) which is characterized by slight to
moderate lung density (granuloma) with involvement of one
or both apices of lungs; moderate disease in addition to the
above features presents with a single cavity (PMD); and
advance disease (PAD) where disseminated confluent lesions
with miliary molting and/or multiple cavities are seen
(Fig. S1). In primary TB infiltration of either the apices, middle,
or lower lung zone can occur with or without hilar lymph
node involvement and in some cases pleural effusions can
also be seen in chest X-rays. The course of radiological recov-
ery in TB patients is variable and may take months to several
years to fully resolve with disappearance of infiltration, lung
lesions, and/or cavities. As expected, PMN lesions usually
show early recovery while PAD shows a slow recovery. How-
ever, PMD, which comprise the majority of patients, shows
variable radiological recovery. In these patients radiology is
not a predictive parameter for the rate of recovery. Therefore,
it is important to identify patients who are likely to show slow
recovery at the time of intake for purposes of closer monitor-
ing. Often slow responders of TB therapy constitute high risk
individuals for relapse and reactivation of TB. This is an
important issue for both clinicians as well as TB control pro-
gram. No clinical or biological markers are available per se to
identify the disease resolution process at the time of initia-
tion of chemotherapy. The role of cytokines in TB disease pro-
gression and treatment has been studied at length [3], but
none of the studies addressed the issue of biomarkers to pre-
dict recovery of TB patients at the time of diagnosis and pre-
treatment. Our current study was therefore unique, as we
carried out parallel assessment of various clinical and
immune biomarkers including T helper cell TH1 and TH2
cytokines serially at 0 months, 6 months, 12 months, and
24 month and correlated them with resolution of clinical
signs, symptoms, and lung lesions. On the basis of tissue
recovery on a chest radiograph, we divided patients into three
categories of response to TB treatment: slow recovery
(>12 months), intermediate recovery (<12 months), and fast
recovery (<6 months) and then applied cluster analyses to
define fast and slow responders. The characterization of TB
patients as slow or fast responders post anti-TB treatment
is important as slow responders are most likely to relapse
and/or develop complications. Pulmonary tissue healing as
assessed with radiology is the only available tool for tissue
recovery but this is also not predictive at intake. A single clus-
ter of interleukin (IL)-2 and -4 levels at initiation of therapy
was able to group TB patients into fast and slow responders
as defined by radiological recovery. These findings may be
useful to clinicians in monitoring TB patients postchemother-
apy for both clinicians and TB control program.Materials and methods
Recruitment of TB patients
As part of a larger cohort longitudinal study [4], 20 families
each with at least one case of sputum-positive TB (index case)
and their exposed household contacts were recruited (from
November 2001 to January 2008). Index cases with active TB
patients were identified at the Masoomeen General Hospital
Karachi located in a low socioeconomic peri-urban area of
Karachi, Pakistan. Only newly diagnosed untreated TB
patients (N = 15) who were sputum positive for acid-fast
bacilli and had <1 month of treatment were included in the
study. TB patients with relapse and a history of past TB treat-
ment were excluded from the study. Any patient with comor-
bid conditions such as diabetes, autoimmune disease, and/or
on steroids for various TB unrelated conditions were also
excluded from study. Study protocol was approved by the
Aga Khan University Ethical Committee. As Karachi is highly
endemic for TB [5], we also included healthy endemic controls
(EC; N = 43) for comparison of baseline cytokine responses.
ECs were derived from the same socio-economic background.
The age and sex distribution and tuberculin skin test (TST)
status of the TB and EC groups is given in Table 1.
Cytometric bead array assay
Cytokine assessment was carried out using human TH1/TH2
cytokine kit II (BD Bioscience, San Jose, CA, USA) for simulta-
neous detection of six cytokines (IL-2, -4, -6, -10, tumor necro-
sis factor-alpha [TNFa], and interferon-gamma [IFNc]) in
plasma and culture supernatants samples as described previ-
ously [5]. All data were acquired on BD fluorescence-activated
cell sorting (FACS) array platform. The cytokine measurement
was based on the principle of cytometric bead array (CBA)
technology. CBA utilizes microparticles or beads labeled with
discrete fluorescence intensity. The capture beads were
labeled with allophycocyanin and were read at 650 nm or on
parameters. The detection antibody specific for cytokines
was labeled with phycoerythrin fluorochrome which emits
at 585 nm on yellow parameters. The intensity of fluorescence
of the yellow parameter is proportional to the amount of cyto-
kine present in test samples. Briefly, test samples (50 lL) and
phycoerythrin detection antibody were incubated with cap-
ture bead reagent for 3 h in the dark at room temperature.
All unbound antibodies were washed (1.0 mL wash buffer)
and resuspended in 300 lL before acquisition on BD FACS
array bioanalyzer (BD Bioscience). All six cytokines had a sin-
gle, well separated peak. Six individual cytokine standard
curves (range, 0–5000 pg/mL) were run in each assay. The
range of detection was between 3000 pg/mL and 5000 pg/mL
and inter- and intra-assay coefficient of variation for all
cytokines have been reported previously from our laboratory
[5] and were in accordance with that provided by the
manufacturer.
Statistical analysis
Statistical analyses were performed using SPSS (version 16.0;
SPSS Inc., Chicago, IL, USA) for Windows. Cluster analysis was
Table 1 – Demographics of study groups.
TB cases Age (y) Sex MT
(Mean ± SD) M/F (Mean ± SD)
PTB (n = 15) 32.06 ± 12.03 3/12 16.53 ± 9.07
EC (n = 43) 29.41 ± 10.69 19/25 7.80 ± 8.00*
Note: EC = endemic control; MT = Montoux test; PTB = pulmonary tuberculosis; SD = standard deviation.
* p = .001 using Student t test.
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response as fast, slow, and intermediate groups on the basis
of radiological recovery in patients. Hierarchical clustering
was performed to measure the distance of similar or dissim-
ilar variables. Similarities between cases were assigned as
one cluster, whereas dissimilar groupswere clustered at a dis-
tant in a dendrogram. The Wald cluster method was applied
to measure squared Euclidean distance. Numeric values were
expressed as mean ± standard error of the mean (SEM) and
significance between groups was assessed using Mann–Whit-
ney U tests. All p values are two-sided with p < .05 considered
as statistically significant.
Results
Characteristics of TB patients and recovery pattern
Pulmonary TB patients were classified into PMN, PMD, and
PAD on the basis of lung tissue involvement as per the guide-
lines of Crofton [6] (Fig. S1). The demographics of the study
group are given in Table 1 which shows the age, sex, and
TST status of TB patients (n = 15) and ECs (n = 43). There was
no difference in the mean age of TB patients and ECs; how-
ever, the mean TST diameter as expected was significantly
higher in the TB patient group compared with the EC group
(Student t test; p = .001). The majority of TB patients were
women, which could be a selection bias of our cohort study,
where index cases and household contacts were recruited in
a longitudinal follow up study [7], as women were found to
be more reliable in longitudinal follow-up studies in families.
TB was confirmedwith sputummicroscopy, chest X-rays, and
signs and symptoms consistent with newly diagnosed TB
patients. All patients were microscopically sputum positive,
and had received <1 month of treatment (Table S1). Clinical
and radiological follow-up of TB patients was carried out
using a standardized questionnaire and reviewed by the chest
physicians of Masoomeen General Hospital. To understand
the dynamics of recovery in pulmonary patients post-
therapy, we analyzed several disease associated parameters
which included signs and symptoms, laboratory tests, and
radiology (Table 2). Detailed signs and symptoms and their
recovery are given in Table S2. Lung tissue healing was vari-
able and the patients were stratified on this basis, into fast
(N = 5) if complete healing occurred in <6 months, intermedi-
ate (N = 4) <12 months, or slow if lesions were present at
>12 months (N = 6; Table S2). Fever was the first symptom to
normalize (14/15 at 6 months) in patients, while erythrocyte
sedimentation rate (ESR), which is a sign of systemic inflam-
mation showed the slowest recovery and was still raised(>30 mm) in 11/15 patients at 24 months (Table 2) even in
the absence of lung lesions.
Relationship of the extent of lung tissue involvement at intake
with radiological recovery of lung lesions post-treatment
We next assessed the radiological recovery in relation to the
extent of disease at intake (Table 3). Of 15 TB cases, 13 had
moderate disease. Furthermore, among those with PMD, eight
had only lung tissue involvement, four PMD had hilar lymph
node (HLN) involvement in addition, and one PMD had pul-
monary effusions (PE). It was interesting to note that HLN
involvement in PMD was associated with fast recovery of lung
lesions, while PE was associated with a much slower recovery
of lung lesions. Recovery in the PMD group with no other site
involved was variable and equally distributed between inter-
mediate and slow responders. Therefore it would be impor-
tant to have predictive biomarkers at initiation of treatment
for this particular group of TB patients.
There was only one TB patient with advanced disease and
had both HLN and PE involvement and as expected showed
slow recovery. There was also one patient with minimal dis-
ease and had only lung involvement. Unexpectedly, this
patient also showed slow resolution of lung lesions.
Plasma cytokines and their relationship with radiological
recovery
We first validated CBAmethodology by comparing the plasma
cytokine levels in the TB (N = 15) and EC (N = 43; Fig. 1) groups.
All cytokines were significantly raised in TB patients com-
paredwith healthy controls as previously reported [4,5]. These
results show that the CBA was able to discriminate cytokine
levels between patients and control groups. We next assessed
the plasma levels at intake within TB patients in relation to
radiological recovery. Frequency of cytokine levels in fast,
intermediate, and slow recovery groups are shown in Fig. 2
as box plots (TH1: IL-2, IFNc, TNFa, upper panel A; TH2: IL-4,
IL-10, IL-6, lower panel B). A significantly higher level of IL-2
and -4 was associated with slow recovery of lung lesions
(p = .027, p = .018) and intermediate recovery (p = .02) of lung
lesions compared with fast responders. Interestingly, there
was no association of any other cytokines with rate of radio-
logical recovery of lung lesions, although there were trends
in other cytokines such as low IFNc and high TNFa associated
with fast recovery, but did not reach statistical significance. To
further confirm the ability of these cytokines to predict rate of
radiological recovery pretreatment, we also applied cluster
analysis as described in the ‘‘Materials and methods” Section.
Fig. 1 – Comparison of circulating plasma cytokines levels in tuberculosis (TB) patients and healthy controls. Comparison of
plasma cytokines in healthy community controls (endemic controls [EC] = 43) and pulmonary TB patients (pulmonary
TB = 15). Cytokineswere analyzed in plasma using human TH1/TH2 cytokine kit II (BD Bioscience, San Jose, CA, USA). Plasma
samples were diluted 1/10 in dilution buffer. All protocols were followed according to manufacturer’s instruction and
analyzed on a BD fluorescence-activated cell sorting array instrument as described elsewhere [5]. Bar graph shows the
plasma cytokine levels diluted 1/10 in assay diluent. All protocols were followed according to manufacturer’s instruction and
analyzed on a BD fluorescence-activated cell sorting array instrument. The results are shown as mean (bars) and ±standard
error (vertical lines). Mann–Whitney U test was applied for significant difference in two groups. All significant p values are
indicated. Solid bar indicates TB patient and open bar indicates healthy control. Note: IFN = interferon; Il = interleukin;
TNF = tumor necrosis factor.
Table 3 – Radiological recovery in relation to extent of pulmonary disease at intake.
TB cases (N) Fast Intermediate Slow
PMN (1) 0 0 1
PMD (8) 1 4 3
PMD-HLN (4) 4 0 0
PMD-PE (1) 0 0 1
PAD-HLN-PE (1) 0 0 1
Total 5 4 6
Note: HLN = hilar lymph node; PE = pulmonary effusions; PMD = presents with minimal disease.
Table 2 – Recovery rate of tuberculosis patients postchemotherapy.
Disease parameters (positive for sign/tested) 0 months 6 months 12 months 24 months
Signs and symptomsa 15/15 6/15 4/15 2/15
Fever 15/15 1/15 2/15 0/15
ESRb 14/15 14 /15 14/15 11/15
Lung lesions 15/15 10/15 6/15 2/15
Note: ESR = erythrocyte sedimentation rate.
a Includes cough, night sweats, and weight loss shown in Table S2.
b ESR > 30 mm/h.
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IL-2/IL-4 cluster analysis
Cluster analysis on plasma cytokines was evaluated at intake.
Fig. 3 shows the dendrogram on circulating levels of IL-2
and -4 cytokines in TB patients. The clusters in the dendro-
gram stratified the fast and slow responders into two distinct
clusters with fast and intermediate responders grouping in
Cluster 1, and slow responders in Cluster 2. IL-2 and -4 there-
fore show a dominant association with the rate of recovery oflung lesions. Only one patient with an intermediate response
(TB 271) grouped with slow responders. In this patient,
although the clinical signs and symptoms resolved at
6 months the lung lesion, although localized, was still present
at 6 months (Table S2).
Cluster analysis on TH1/TH2 combinations
It is likely that additional cytokines may also affect response
rate. To address this issue we combined additional cytokines
in the cluster analysis as shown in Table 4. Adding IFNc to the
Fig. 2 – Relationship of radiological recovery with pro- and downregulatory cytokines. All details are the same as Fig. 1. The
results are shown as box andwhiskers plot indicating 25th, 50th, and 75th percentiles of cytokines in three categories of fast
(n = 6), intermediate (n = 4), and slow (n = 5) responders. Mann–Whitney U test was applied for significant difference in two
groups. All significant p values are indicated. Note: IFN = interferon; Il = interleukin; TNF = tumor necrosis factor.
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The addition of IL-10 to existing IL-2 and -4 clusters to some
extent stratified slow and fast responders and divided them
into Clusters 2 and 3 but an additional cluster with fast and
intermediate were also found as Cluster 1. Additional cytoki-
nes therefore failed to provide useful information but did sug-
gest that some effect may be exerted by other cytokines on
the rate of recovery. However, it is clear that PMD, whichFig. 3 – Cluster analysis of interleukin-2 and -4 for discriminati
dendrogram represents individual cases numbered on the vertic
data was standardized using Z-score. The horizontal line separa
shows the serial number of unique identifier in SPSS database
response of individual patients as fast, intermediate, and slow.forms the majority of TB patients, could be defined as fast
and slow responders with IL-2 and -4 clusters pretreatment.
Frequency of plasma levels IL-2 and -4 cluster
We next determined if a cut-off level could be defined for slow
and fast responders with IL-2 and -4. Fig. 4 shows the bar
graph of mean ± SEM of IL-2 and -4 cytokines in Clusters 1on of fast, intermediate, and slow responders. The
al axis. The cluster was analyzed using Wards method and
tes the two clusters (Cluster 1 or Cluster 2). The vertical axis
with case identification. Vertical axis also defines the
Note: TB = tuberculosis.
Table 4 – Summary of cytokine clustering in relation to rate of radiological recovery.
Note: C = cluster; HLN = hilar lymph node; ID = identification; IFN = interferon; IL = interleukin; Int = intermediate; PAD = advance disease;
PE = pulmonary effusions; PMD = minimal disease; TB = tuberculosis.
Majority of cluster 1 (C1) cases are highlighted in yellow, cluster 2 (C2) in Pink and cluster 3 (C3) in green.
Fig. 4 – Differential cytokine secretion pattern in Clusters 1 and 2. Bar graph shows the distribution (mean ± standard error of
the mean) of plasma cytokines in two clusters (Clusters 1 and 2) as mentioned in Fig. 3. Results are shown as pg/mL for
interleukin-2 and -4. Mann–Whitney U test was applied for comparison of cytokines in Cluster 1 (n = 8) and Cluster 2 (n = 7).
Note: IL = interleukin.
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levels (p = .001) in the slow responder (Cluster 1) compared
with the fast responders group (Cluster 2). A cut off of
>50 ng would seem a reasonable cut off for discriminating
the two groups. This level is 10-fold above the detection range
and therefore can be reliably detected in CBA. These levels,
therefore, could be used as predictive markers but further
studies are needed with expanded groups to improve the
power of prediction for the rate of recovery.
Discussion
This study aimed at defining immune markers at initiation
of chemotherapy associated with recovery of radiological
lesions which is the gold standard for assessment of suc-
cessful treatment. Serial radiology over the treatment per-iod has shown considerable variability in the rate of
recovery in TB patients, but is not a practical test at the
field level. Therefore, a single test at the time of initiation
of therapy is necessary which would predict slow and fast
recovery. This is particularly important for TB control pro-
grams. This is what we attempted to define in the current
study.
In the present study we classified TB patients with fast,
slow, and intermediate response to therapy, based on the
radiological recovery post-treatment in a 2 year follow-up. It
was surprising that of the six cytokines tested only two
cytokines, IL-2 and -4, were dominantly associated with the
rate of recovery of lung lesions. The cytokine levels were sig-
nificantly higher in TB patients compared with the EC groups
and considerably above the baseline levels of detection and
therefore can be reliably assessed in this assay.
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patients with moderate disease into slow and fast responders.
Patients withmoderate disease form the major group in Bacil-
lus Calmette–Gue´rin (BCG) vaccinated countries which may
be due to the partial protection conferred by BCG vaccination.
Therefore, these findings provide important information for
countries with a high rate of TB transmission despite BCG
vaccination.
Immune markers which discriminate slow and fast
response during intensive TB therapy has been attempted
previously [8]. However, none of the studies succeeded in
identifying predictive immune biomarkers. This is mainly
due to logistic challenges and use of nonstandardized assays
[9,10]. Certain statistical models could discriminate slow from
fast responders with immune makers at the time of diagnosis
and 4-weeks post-treatment [8,11]. In those studies, mathe-
matical models predicted soluble TNF receptor-1, C-reactive
protein [11], granzymes [8,12], and IP-10 [13] as biomarkers
of TB treatment response. In our previous study we attempted
to classify immune response according to severity of pul-
monary disease using lymphoproliferative assay and purified
protein derivative skin test [14]. Our results indicated an asso-
ciation of higher lymphoproliferative assay response in PMN
compared with PAD. However, this study did not carry out a
serial follow-up of TB patients.
Most studies defined TB patients as slow responders if they
remained sputum positive after 2 months of intensive treat-
ment to monitor patient progress [15]. The bacterial load also
correlated with a higher level of immune markers such as
granzyme B, monocytes, and neutrophils after 4-weeks post-
treatment [8]. Bacterial load can be deceptive as both dead
and live bacteria may be included and this may be the reason
as to the extent of disease not relating to the bacterial load.
The main strength of our study was the serial assessment of
chest X-rays and laboratory tests over a period of 24 months.
Our classification of slow and fast responders was not based
on bacterial load but rather healing and disappearance of
lesionswhich ismore likely to be a better assessment of recov-
ery. The baseline assessment of biomarkers to reliably predict
outcome of TB disease in terms of slow and fast response to
therapy is highly desirable for targeted intervention. However,
the low reversion rate of IFNc release assays post-treatment
and inconsistent results in TB treatment [16,17] directed us
toward high throughput multiplex estimation of cytokines to
predict recovery of patients before the start of treatment.
The majority of studies assessed serum cytokines in TB
patients between 8 weeks and 12 weeks post-treatment; the
findings were equivocal to determine the predictive value of
each or combined biomarkers. Most studies showed an appar-
ent decrease in cytokine response post-treatment between
0 months and 6 months [18–20].
In our study, the radiological recovery was consistent with
sputum clearance and no patients had multi-drug resistant
TB. All patients had sputum conversion within 6 months.
One of the limitations of our study was that no follow-up
was done at 2 months for smear conversion. However, the
long follow-upwasmore critical as thiswas themain strength
of the study. Fever was the earliest to resolve while ESR took
the longest time to resolve and was elevated in some patients
even at 24 months. Fever may therefore be related to antigenclearance while ESR may be related to immune activation of
proinflammatory cytokines which takes longer to down regu-
late and decrease to baseline levels. This may be the reason as
to why inflammatory markers have not been useful indicators
of resolution of disease. This was also clear in our current
study where both predictive markers are involved in either T
cell proliferation or differentiation (IL-2) or released from dif-
ferentiated T cells, while none of the proinflammatory mark-
ers such as IFNc, TNFa and IL-6 showed association with
tissue healing. The radiological recovery in a few patients
was slow, but none of the patients showed relapse in our
group. Interestingly the additional sites involved also had an
influence in tissue healing particularly in patients with mod-
erate disease. HLN involvement was predictive of a faster
response to treatment while PE usually was associated with
a slower rate of recovery in patients with moderate disease.
We have not tested drug resistance in the current study group
which has been previously reported in this endemic setting
[21]. The reason for the high response ratemay be due to com-
pliance to the multidrug regimen. Additionally, patients had
no prior history of TB treatment or relapse.
The hierarchical clustering for IL-2 and -4 was most dis-
criminatory for classification of TB patients in two distinct
clusters and properly assigned 100% of slow responders into
Cluster 2 associated with raised IL-2 and -4 levels at baseline
(Fig. 4). Similarly high pretreatment levels of other cytokines
have been reported in patients showing slow response to
treatment, and were labeled as late responders [19,20]. The
definition of late responders in these studies was sputum
positive culture after 2 months of treatment. We have previ-
ously reported a consistent high spontaneous IL-4 secretion
in recently exposed household contacts of active TB cases,
which progressed to TB disease [22]. These findings indicate
that raised IL-4 may be a risk factor even before the establish-
ment of TB disease [22]. Spontaneous IL-2 was also shown to
be raised in exposed household contacts progressing to dis-
ease but the levels were not significant [22].
Several reports indicate that there is no change in IL-2
and -4 levels after TB treatment [23,24]. These studies were
carried out in human immunodeficiency virus (HIV) infected
cohorts [24]. HIV is known to influence the baseline levels of
anti-inflammatory cytokines. Pakistan has less than one
prevalence of HIV in a TB-infected patient [25] and this may
be the reason for discriminatory levels not only in TB patients
compared with healthy ECs, but may also be the reason for
discrimination in patients with varying severity of TB disease.
Onestudyalso reportedahigherphenotypeof IL-2+ incured
TBpatients in the centralmemory pool anda lower response in
the effectormemory pool [26]. Higher frequency of IL-2+ T cells
was found in the bronchial lavage compared with peripheral
blood [27] and an increase in double positive IFNc+/IL2+ T cells
post-treatment [28,29]. These resultsmay seemdiscrepant, but
the explanation may be linked the different compartments
being assessed, i.e., cellular frequency of IL-2+ T cells versus
plasma levels. Different compartments in blood are known to
show higher or lower frequency in the same patient or control
group depending on the compartment being assessed [30]. In
additionmostof these studiesare cross sectional and therefore
information on both the classification of TB patients and
response to treatment was not available.
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In conclusion, we have identified biomarkers in pulmonary
TB patients which may predict the rate of recovery at time
of initiation of chemotherapy. Radiology, although a gold
standard for lung lesion recovery, is difficult to carry out
repeatedly in field conditions and also does not predict the
rate of recovery at time of initiation of chemotherapy as
demonstrated in our study. Therefore identification of these
predictive biomarkers is a step forward in improving not only
the management of TB patients at the time of initiation of
chemotherapy but will also help TB control programs in iden-
tifying high risk patients for reactivation and relapse and
those who pose a threat to control activities.
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